← Leaderboards
Richard M. Van Rijn
Ernest Gallo Clinic And Research Center
$2,970,840
Attributed
$3,111,047
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $775.1K · FY2011–20$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,111,047 · 6
By mechanism
R01$1,353,515 · 1
R00$727,900 · 1
R21$701,889 · 2
K99$178,419 · 1
R03$149,324 · 1
Top collaborators
- Michael Keith Wendt2 shared
Most similar at Ernest Gallo Clinic And Research Center
Same institution · by research overlap
- Elyssa Margolis$8,491,582
- Dorit Ron$22,439,958
- Michael F. Miles$16,112,702
- M. Foster Olive$11,163,278
Others in their field
Top investigators on “Alcohol Consumption”
- Richard A Miech · Johns Hopkins University$46,450,970
- Adolf Pfefferbaum · Sri International$37,828,119
- Amy Caroline Justice · Philadelphia Va Medical Center$37,631,036
- Kathleen A Grant · Oregon Health & Science University$33,412,314
- Marisa Roberto · Scripps Research Institute, The$30,508,961
- Lloyd D Johnston · University Of Michigan At Ann Arbor$28,120,019
Research focus
Alcohol ConsumptionG-Protein-Coupled ReceptorsAlcohol ExposurePropertyOpioidOpioid ReceptorPharmaceutical PreparationsAgonistReceptorPharmacologyPhysiologicalAdverse EffectsRelapseAlcohol Withdrawal SyndromePlayAnxietyDrug UsageAffectIn VitroAnti-Anxiety AgentsSignal TransductionAlcoholsFutureBeta-Arrestin
Grant awards (15)
G-protein-, beta-arrestin- and ERK-signaling in alcohol use- and anxiety-disorders$338,120
R01 · FY2020 · AA · contact PI
G-protein-, beta-arrestin- and ERK-signaling in alcohol use- and anxiety-disorders$338,329
R01 · FY2019 · AA · contact PI
Opioidergic alkaloids from Mitragynia Speciosa (kratom) as novel treatment for alcohol use disorder$221,951
R21 · FY2019 · AA · contact PI
The influence of alcohol on the metastatic dormancy of breast cancer$140,207
R21 · FY2019 · AA
Development of G-protein biased delta opioid receptor agonist with analgesic potency$74,662
R03 · FY2019 · DA · contact PI
G-protein-, beta-arrestin- and ERK-signaling in alcohol use- and anxiety-disorders$338,533
R01 · FY2018 · AA · contact PI
Opioidergic alkaloids from Mitragynia Speciosa (kratom) as novel treatment for alcohol use disorder$199,524
R21 · FY2018 · AA · contact PI
The influence of alcohol on the metastatic dormancy of breast cancer$140,207
R21 · FY2018 · AA
Development of G-protein biased delta opioid receptor agonist with analgesic potency$74,662
R03 · FY2018 · DA · contact PI
G-protein-, beta-arrestin- and ERK-signaling in alcohol use- and anxiety-disorders$338,533
R01 · FY2017 · AA · contact PI
Development of a preclinical candidate for the treatment of alcoholism$237,370
R00 · FY2015 · AA · contact PI
Development of a preclinical candidate for the treatment of alcoholism$241,531
R00 · FY2014 · AA · contact PI
Development of a preclinical candidate for the treatment of alcoholism$248,999
R00 · FY2013 · AA · contact PI
Development of a preclinical candidate for the treatment of alcoholism$88,419
K99 · FY2012 · AA · contact PI
Development of a preclinical candidate for the treatment of alcoholism$90,000
K99 · FY2011 · AA · contact PI